

15<sup>th</sup> January, 2020

The Dy. General Manager (Listing Dept.)  
BSE Limited.,  
Corporate Relationship Dept.,  
1st Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: Intimation of the date of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

We would like to inform you that:

1. A meeting of the Board of Directors will be held on Monday, 27-Jan-20, *inter alia* to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-19.
2. In the above meeting, the Board would also consider the following:
  - i. Payment of Interim Dividend for the year 2019-20.
  - ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes.

If such issue of Equity shares is approved by the Board of Directors, Shareholders' approval will be taken through postal ballot.

Kindly take note of the above.

Thanking you,

Yours' Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

  
MAHESH AGRAWAL

VP (LEGAL) & COMPANY SECRETARY